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Abstract
Background: Ciclosporin is a selective immunomodulator used for the treatment of atopic dermatitis in dogs. A
new 100 mg/ml oral solution formulation (Cyclavance®, Virbac) was developed as a pharmaceutical equivalent to
the marketed capsule formulations (Atopica®, Novartis Animal Health) containing 25, 50 mg, or 100 mg of
ciclosporin A. The aim of this study was to assess and compare the pharmacokinetic profiles and bioequivalence of
the two formulations following a single oral administration to dogs. This randomised, two-period, two-sequence,
crossover bioequivalence study was conducted in 40 healthy dogs under fasting conditions. Each dog received
either one 50 mg capsule of Atopica® or 0.5 ml of Cyclavance®. After dosing, blood samples were collected during
a 48-h time period at 0, 0.5, 1, 2, 4, 6, 12, 24, 36 and 48 h. Blood ciclosporin A concentrations were measured by
using an HPLC-MS/MS method. Cmax, Tmax, t1/2, AUC0-t, AUC0-∞ and Kel were determined for the two
ciclosporin formulations. Bioequivalence was to be concluded if the 90 % confidence intervals were within the
range of 80 % to 125 % for Cmax and AUC0-t. Dogs were monitored once daily throughout the study period for
adverse effects.
Results: The 90 % confidence intervals for Cyclavance®/Atopica® mean ratios of the log-transformed
pharmacokinetic variables Cmax and AUC0-t were within the conventional bioequivalence range of 80 % to 125 %
(Point estimate: 101.2 % and 101.4 % respectively). Except for salivation reported after administration of both
products, or vomiting and diarrhoea reported after Atopica® administration, both formulations were well tolerated
in the 40 healthy dogs over the 48-h study period.
Conclusions: The two ciclosporin oral formulations demonstrated similar pharmacokinetic profiles and were found
to be bioequivalent, and therefore, interchangeable.
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Background
Ciclosporin is a calcineurin inhibitor with potent immuno-
suppressive and immunomodulatory activities resulting
from decreased production of interleukin-2 and prolifera-
tion of T-cells [1, 2]. It reduces the number and activity of
proinflammatory cells which induce activation of cells ini-
tiating the cutaneous immune response (Langherans’ cells
and lymphocytes) and cells mediating allergic reactions
(mast cells and eosinophils). As a result to this inhibition,
ciclosporin exhibits strong anti-allergic effects and anti-
inflammatory activity [3, 4].
Ciclosporin has been used in veterinary dermatology
for the control of allergic chronic diseases for more than
a decade [2]. A growing number of studies have investi-
gated the efficacy and safety of ciclosporin in the treatment
of canine atopic dermatitis [1–3, 5–8].
The International Task force on Canine Atopic
Dermatitis 2010 practice guidelines concluded that there
was good evidence for high efficacy of ciclosporin at
5 mg/kg once daily in the treatment of dogs with atopic
dermatitis [6].
Atopica® soft capsules, a tablet formulation of ciclos-
porin A available in 25, 50, and 100 mg soft gelatin cap-
sules, is approved for use in canine atopic dermatitis and
has been available since 2002. Previous pharmacokinetic
studies on Atopica® soft capsules in dogs, have shown
that ciclosporin is rapidly absorbed, principally from the
small intestine [1, 2], with mean peak blood concentra-
tions achieved 1–2 h after oral administration [9]. Bio-
availability is however variable and can range from 23 %
to 45 % [1, 2]. This low and highly variable absolute oral
bioavailability can be explained by the high molecular
weight of the drug, its low water solubility, the effect of
the P-glycoprotein efflux pump at the intestinal level,
and metabolism by cytochrome P450 3A enzymes lo-
cated in the small intestinal mucosa and liver [1, 2, 8].
Furthermore, because the bioavailability of ciclosporin
in dogs decreases when given with food, the recom-
mendations are to administer the drug 2 h before or
after feeding [1, 2]. Being lipophilic, ciclosporin distrib-
utes widely in the tissues and its concentration in epi-
dermis and dermis is about 10-fold higher than in the
blood [1, 2, 8]. Elimination is mainly biliary with min-
imal renal excretion [1, 2, 8]. The relatively long half-
life of the drug (8.6 h) [9] and its concentration in the
skin after oral administration [10] support once daily
dosing in dogs.
A new oral liquid formulation (Cyclavance®) of ciclos-
porin A is now available for dogs in Europe and facili-
tates precise dosing and owner compliance [11]. In
human medicine, studies comparing the bioequivalence
and pharmacokinetic conversion of Neoral® product
(Novartis, original formulation) with that of Equoral®
product (Teva, generic formulation) have demonstrated
that these drugs are bioequivalent and interchangeable
in stable patients [4, 8].
The objective of this study was to compare the phar-
macokinetic profiles of Cyclavance® oral solution and
Atopica® soft capsules dosed on an empty stomach in
order to evaluate their bioequivalence and consequently




The study was performed on 40 male, adult and healthy
beagle dogs. The animal bodyweight ranged from 8.775
to 10.860 kg. The dogs were housed in pens and fed
daily with ration of an adapted pelleted feed, with access
to water ad libitum.
Housing room temperatures were recorded daily and
ranged from 13.8 °C to 21.4 °C.
All animals were managed similarly with due regard
for their well-being according to prevailing practices
(Directive 86/609/EEC).
Formulations
The commercially available reference product containing
ciclosporin A, Atopica® 50 mg soft capsules for dogs
(Novartis Animal Health.) and Cyclavance® oral solution
containing the same active ingredient, ciclosporin A
100 mg/ml oral solution (Virbac SA) were used to carry
out the current study.
Study design
The study was conducted in a single dose, randomised,
two-period, two-sequence, cross-over design with a 8-day
washout period between treatment.
The 40 animals were randomly allocated into two treat-
ment groups: a single dose of 50 mg ciclosporin capsules
(Atopica®) or 0.5 ml oral solution (Cyclavance®) was ad-
ministered to the fasted dogs.
After dosing, blood samples were collected during a
48-h period. Blood samples of 2 ml each were drawn at
0, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36 and 48 h after
administration.
Animals were fasted at least 15 h before each treat-
ment and were fed after the 4-h post-treatment sam-
pling. Animals had free access to water. Animals were
observed once daily for any adverse events.
The project was evaluated and approved by the ethical
committee of AmatsiAvogadro. It was conducted in
accordance with the principles of Good Laboratory
Practices (EC principles of Good Laboratory Practices,
Directives 2004/10/EC of the European Parliement) and
according to Guidelines for the conduct of pharmacoki-
netic studies in target animal species (EMEA/CVMP/
133/00-FINAL) and Guidelines for the conduct of
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bioequivalence studies for veterinary medicinal products
(EMA/CVMP/016/00-Rev.2).
Analytical method
Blood ciclosporin A concentrations were determined
using an HPLC-MS/MS method previously validated for
specificity, sensitivity, linearity, recovery, precision, ac-
curacy, stability. A mixture of red blood cells and pro-
teins in 0.1 mL blood fortified with internal standard by
addition of 0.2 mL 0.1 % formic acid in acetronitrile was
vortexed. The mixture was vortexed again after addition
of 0.4 ml of ammonium acetate (20 mM) and 3 ml of
tert-butyl-methyl-ether. The supernatant was evaporated
to dryness and the residue dissolved in 0.2 ml of recon-
stitution solvent. Then the sample was assayed by re-
versed phase HPLC with methanol/water (gradient over
12 min) as mobile phase, using a C18 column, detection
by MS/MS (MRM transition: 602.2 > 100.1) and quanti-
tation by peak area using ciclosporin A -D12 as internal
standard. The calibration curve was prepared with forti-
fied blood specimens of untreated animals combined
with the internal standard and enabled the recovery-
corrected determination of ciclosporin A in unknown
specimens. The calibration curve performed from the
assay ranged from 10 ng/ml (Lower limit of quantifica-
tion: LLOQ) to 2000 ng/ml (Upper limit of quantifica-
tion: ULOQ). The validation of the method yielded a
mean recovery of 76.6 % and a precision with a coeffi-
cient of variation of 5.0–8.0 % for repeatability. Matrix
effect was not observed. Only concentrations equal or
exceeding the LLOQ were used.
Pharmacokinetic and statistical analysis
The sample size was calculated on the basis of a cross-
over design with log-transformed data according to
Hauschke et al. [12], considering an intra-individual
variation coefficient of 22.7 %, a power of the test of
80 %, a confidence interval of 80–125 %, an expected ra-
tio μT/μR (mean of test versus reference) of 1.10, based
on Steffan et al. [13].
Under these conditions, the calculated sample size was
40 animals.
The highest blood concentration observed and the
corresponding time was defined as the Cmax and Tmax
values, respectively. The terminal rate constant (Kel) was
obtained by linear regression of the log-linear terminal
phase of concentration-time profile using at least 3 con-
secutive data points and starting from the last non zero
value. The terminal half-life (t1/2) was obtained as ln2/
Kel. AUC0-t (area under the curve between time 0 and
time of the last quantifiable value) was calculated by the
mixed log-linear method. The extrapolated AUC
(AUC0-∞) was calculated from the computed last quan-
tifiable blood concentration divided by Kel and the
percentage of extrapolated AUC (%AUC0-∞) was ob-
tained using the following formula: %AUC0-∞ = (AUC0-
∞/(AUC0-∞ + AUC0-t)) x100.
The pharmacokinetic parameters were generated using
WinNonlin software version 6.1 (Pharsight).
In accordance with the general recommendations, the
analysis of variance was performed after logarithmic
transformations of the parameters AUC0-t and Cmax. A
statistical comparison of the pharmacokinetic parame-
ters Cmax and AUC0-t was performed by a mixed ef-
fects model analysis. Alpha risk was of 0.5 %.
For the pivotal parameters AUC0-t and Cmax, bio-
equivalence was determined when the 90 % confidence
interval of these two parameters were within 0.8 and
1.25.
Results
Salivation was observed for 6 animals (5 receiving Cycla-
vance® oral solution and 1 receiving Atopica® soft cap-
sules) on period 1. For one animal, the effect was
observed before and after administration of the product.
Similar observations were done on three animals (2
receiving Cyclavance® oral solution and 1 receiving Ato-
pica® soft capsules) on period 2. As salivation was ob-
served before treatment and was less frequent in period
2, it was concluded that it was due to the stress of ani-
mals at the start of the study. One animal vomited
29 min after administration of Atopica® soft capsules.
The empty capsule was found in the vomit. The animal
was not excluded from the study. Diarrhea was observed
in the box of one animal receiving Atopica® soft capsules
at 30 min sampling time. No other abnormal findings
were observed on animals during the study. Bodyweights
of the dogs did not differ significantly over the study
duration (9.754 kg and 9.697 kg for the dogs receiving
Atopica® soft capsules and 9.668 kg and 9.568 kg for the
dogs receiving Cyclavance® oral solution, respectively on
D0 and D8).
Blood concentrations are presented in Table 1 and il-
lustrated in Figs. 1 and 2. For the mean concentration
calculation, BLQ values were set as 0. The pharmacoki-
netic parameters obtained after a single oral administra-
tion of Atopica® soft capsules or Cyclavance® oral
solution are presented in Table 2. The pharmacokinetic
parameters were not dose normalized. Consequently,
AUC and Cmax were not divided by the administered
dose. The low extrapolation for AUC0-∞ demonstrated
that sampling times were adapted, and therefore, that
the terminal half-life was relevant of the elimination of
ciclosporin A.
The upper and lower limits of the calculated confi-
dence intervals are presented in Table 3.
Analysis of bioequivalence between both products
showed that 90 % Confidence Interval for Cmax and
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AUC0-t were within 80 % and 125 % (96.29 % and
106.29 % for the Cmax and 96.21 % and 106.92 % for
the AUC0-t). No sequence, treatment and period effects
were observed for each studied pharmacokinetic
parameters.
Discussion
As defined by the European Medicines Agency [14], bio-
equivalence techniques are scientific methods for the
comparison of different veterinary medicinal products
containing the same active substance. Bioequivalence
testing aims to demonstrate that two medicinal products
produce plasma concentrations similar enough to con-
clude that the systemic effects of the two products, in
respect to efficacy (and possibly safety), are the same.
According to the guidance specifying requirements for
the design, conduct, and evaluation of bioequivalence
studies for veterinary medicinal products with systemic
action [14], generics should be tested against Brand in
healthy animals of the target species and from a
homogeneous group, by giving a single dose of the refer-
ence formulation and the generic formulation that is be-
ing tested. Bioequivalence studies should be performed
using AUC and Cmax to demonstrate that the generic
has similar pharmacokinetics as the brand formulation.
AUC serves as a surrogate for the extent of absorption
whereas the Cmax and the time of its occurrence
(Tmax) together characterize the rate of absorption.
Two veterinary drugs are considered bioequivalent if the
upper and lower limits of the 90 % confidence interval
of the generic-to-brand ratio for AUC0-t and Cmax falls
within the range 80–125 % [14].
Conducted in healthy dogs and in a single dose, rando-
mised, two-period, two-sequence, cross-over design with
a 8-day washout period between treatment, the present
study met applicable standards for bioequivalence stud-
ies in animals [14]. Furthermore, sampling times chosen
in accordance with the EMA guidelines and the use of a
previously validated LC-MS/MS method for measuring
blood ciclosporin A levels, enabled to accurately
characterize the plasma concentration-time profile of
the two drugs. Indeed, LC-MS/MS has been described
as one of the most sensitive, reliable and fast analytical
technique for bioequivalence studies [15, 16] and is
commonly used for determining ciclosporin A levels [1].
When Cyclavance® oral solution and Atopica® soft cap-
sules were administered orally at a target dose of 5 mg/
kg body weight of ciclosporin A, the parametric 90 %
confidence intervals of the mean ratio test/reference
were actually included within the reference confidence
interval [0.80–1.25] for Cmax and AUC0-t parameters.
Otherwise, the values of the pharmacokinetics parame-
ters observed in this study for Atopica® soft capsules are
close to those reported in previous studies using an
HPLC assay [9, 13]. The mean Tmax value was 1.24 h
compared to 1 to 2 h mentioned by Guaguère et al. [9]
and the mean terminal T1/2 value of 9.13 h found in the
present study was within the range (5–11 h) described
by Guaguère et al. [9]. The Cmax value was 772.18 ng/mL
Table 1 Mean ± SD ciclosporin A concentrations (ng/mL)








0.5 354.18 ±206.45 491.54 ±300.01
1 697.09 ±224.49 712.68 ±231.95
1.5 695.48 ±169.80 662.00 ±176.35
2 547.09 ±139.04 524.47 ±160.45
4 251.56 ±73.61 250.15 ±76.41
6 158.27 ±56.38 158.55 ±56.26
12 68.24 ±31.77 69.86 ±33.72
24 30.97 ±18.92 30.65 ±16.29
36 12.29 ±10.40 11.96 ±9.75
48 6.21 ±8.24 6.73 ±7.92





































Fig. 1 Mean ciclosporin A concentrations obtained in dog blood (with linear scale)
Navarro et al. BMC Veterinary Research  (2016) 12:54 Page 4 of 6
slightly above the value reported by Steffan et al. [13]
(577 ng/mL). The statistical analysis was performed with
all animals, including animal for which vomit was ob-
served 30 min after the administration of Atopica® soft
capsules. For this animal, the pharmacokinetic profile of
Atopica® soft capsules seemed to be altered by this ob-
servation since Cmax and AUC values were lower after
administration of Atopica® soft capsules than after ad-
ministration of Cyclavance® oral solution. However, the
inclusion of this animal in the statistical analysis did not
affect the assessment of the bioequivalence between
both products.
Although 40 dogs were used in a cross-over design in
this study, blood concentrations of ciclosporin A showed
quite large inter-animal variations during the 48-h
period following drug administration. Indeed, standard
deviations varied between 8.24 and 224.49 in the dogs
receiving Atopica® soft capsules and between 7.92 and
300.01 in the dogs receiving Cyclavance® oral solution.
Such variations had already been found in a clinical trial
on perianal fistulas as well as in another pharmacoki-
netic study [13]. Many other studies however indicated
that drug absorption and metabolism were relatively
constant in healthy dogs [9, 13]. Even if the reasons for
this discrepancy could not be identified [13], they may
be explained in part by the relatively low bioavailability
of ciclosporin A due to the large molecular mass of the
drug, its low water solubility, as well as its partially
metabolization and limited absorption in the intestines
[9]. In dogs, the bioavailability of the drug administered
orally as a vegetable oil-based formulation is in the range
20–27 % whereas dedicated formulations to dogs offer a
35 % bioavailability [9]. As a consequence, by increasing
absolute bioavailability and reducing biliary secretion,
specific dog ciclosporin A formulations tend to decrease
the interindividual variability of drug absorption [9].
In man, ciclosporin has a <2-fold difference between
the minimum toxic concentration and minimum effect-
ive concentration in blood [17, 18], and the debate as to
whether or not it is necessary to apply stricter guidelines
for such narrow therapeutic index drugs has been on-
going for several decades in human health. Indeed, it has
been suggested that the usual acceptance interval for
AUC and Cmax may need to be tightened to 90 % to
112 % for such drugs, but there is currently no inter-
national consensus on the subject [17, 18]. However,
even if the pharmacokinetic properties of ciclosporin are
very similar in dogs and man, its safety margin is much
wider in dogs [9]. Therefore, more restrictive criteria are
not necessary for assessing bioequivalence of ciclosporin
formulations in dogs. Nevertheless, the results of the
present study show that the criteria proposed in man
were largely met anyway since the intervals were 96.29































Fig. 2 Mean ciclosporin A concentrations obtained in dog blood
(with semi-log scale)
Table 2 Descriptive statistics for pharmacokinetic parameters
Treatment type kel t1/2 Tmax Cmax AUC0-t AUCtot % AUC 0-∞
(1/h) (h) (h) (ng/mL) (h.ng/ml) (h.ng/ml) (%)
Atopica® soft capsules Mean 0.076 NA 1.24 772.18 3680 3901 5.8
SD 0.037 NA 0.32 163.8 1263 1336 1.4
CV% 49.4 NA 25.6 21.2 34.3 34.3 23.3
Harmonic Mean 0.066 9.13 1.16 734.53 3279 3489 5.5
Min 0.044 3.23 0.50 361.39 1236 1334 3.5
Max 0.214 15.75 2.00 1121.98 7763 8393 8.5
Cyclavance® oral solution Mean 0.073 NA 1.12 786.97 3728 3955 5.8
SD 0.026 NA 0.36 188.3 1243 1305 1.3
CV% 35.7 NA 32.5 23.9 33.3 33 22.3
Harmonic Mean 0.064 9.55 1 736.31 3339 3549 5.6
Min 0.030 5.56 0.50 334.61 1654 1740 3.7
Max 0.125 23.08 2.00 1106.28 6907 7170 9.8
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In human health, the scientific aspects of bioequivalence
that govern the use of generics are sometimes described
ambiguously in the literature, and they are therefore not al-
ways perceived clearly by health professionals. This lack of
clarity may be an obstacle to their use [17]. However, ac-
cording to the US Food and Drug Administration [19], if a
drug product contains a drug substance that is chemically
identical and is delivered to the site of action at the same
rate and extent as another drug product, then it is equiva-
lent and can be substituted (switchable) for that drug prod-
uct. Methods used to define bioequivalence in orally
administered drugs as stated by the FDA rules [20, 21] are
pharmacokinetic studies in healthy patients. Consequently,
the present study conducted in dogs in accordance with
FDA and EMA rules clearly demonstrated the switchability
of Atopica® soft capsules with Cyclavance® oral solutions
when dosed orally at 5 mg/kg of bodyweight.
Conclusions
This study demonstrates the bioequivalence between
Cyclavance® oral solutions and Atopica® soft capsules.
Since determining bioequivalence guaranties the inter-
changeability of the brand-name and generic drugs, it
can be concluded that a dog taking one formulation will
be able to change to another that will provide the same
efficacy and safety. The oral liquid formulation of Cycla-
vance® solution enables accurate dosage of ciclosporin
and is convenient and easy to use thus favoring compli-
ance. In conclusion, Cyclavance® oral solution represents
an interesting therapeutic option in the long-term man-
agement of atopic dermatitis in dogs.
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